Throughout the 1990s, Amgen continued in the same vein, investing heavily in R&,D, expanding its sales and bringing out new medications such as Infergen, an anti-hepatitis C medication ...
Amgen and CytomX Therapeutics have kicked a phase 1 T-cell engager to the curb, axing the asset after assessing the clinical data and their pipeline priorities. CytomX signaled the EGFRxCD3 ...
HYDERABAD, India (Reuters) - U.S. drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further investments planned, CEO Robert Bradway said ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback